All In Biotech

Drug Trial Radar · NCT06652438

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Randomized Study to Assess Revumenib in Combination With Azacitidine + Venetoclax in Adult Patients With Newly Diagnosed NPM1-mutated or KMT2A-rearranged AML Ineligible for Intensive Chemotherapy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 448 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

448

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

Dec 13, 2029

Study completion Aug 27, 2032

Sponsor

Lead sponsor
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
German-Austrian Acute Myeloid Leukemia Study Group; United Kingdom AML Research Network; Beat AML, LLC
First posted
Oct 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Treatment of patients with newly diagnosed AML who are not eligible for intensive chemotherapy has remained an area of high unmet medical need. The combination therapy with two medicines, azacitidine and venetoclax, is the usual plan of action. This has brought significant progress in the treatment, but it nevertheless is not curative and the disease does relapse over time. Revumenib blocks a specific molecule called menin in the cell nucleus. Some types of AML are reliant on menin working properly. These are leukemia cells with a change in the DNA, i.e. a mutation in the NPM1 or KMT2A gene. Revumenib can prevent the production of these types of leukemia cells by disrupting the production of this menin. The current study investigates whether adding revumenib to the combination therapy improves the prognosis for AML patients with a mutation in the NPM1 or KMT2A gene. This is a randomized, double-blind, placebo-controlled clinical study where subjects will be treated until disease progression, or development of side effects or death. From the moment of inclusion of the last patient, there will be a 4-year observational follow-up study in order to register survival duration and follow-up visits. Approximately 448 previously untreated patients with a mutation in the NPM1 or KMT2A gene and with newly diagnosed AML, who are not eligible for intensive chemotherapy. Patients must be ≥18 years of age.

Conditions

  • Acute Myeloid Leukemia, Adult

Interventions

  • RevumenibDrug

    day 1- 28 per cycle

  • PlaceboDrug

    day 1- 28 per cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS) in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapy.Time frame: 58 months after last patient inclusion
  2. Rate of CR in adult patients with newly diagnosed NPM1-mutated AML ineligible for intensive chemotherapyTime frame: 58 months after the first randomized NPM1-mutated AML patient

Locations

199 sites in 18 countries. Site status is shown where the registry gives one.

  • US-Los Angeles CA-UCLA

    Los Angeles, California · Not yet recruiting

  • US-San Francisco CA-UCSF

    San Francisco, California · Recruiting

  • US-Atlanta GA-EMORY

    Atlanta, Georgia · Recruiting

  • US-Kansas City KS-KUMC

    Fairway, Kansas · Recruiting

  • US-Baltimore MD-UMGCCC

    Baltimore, Maryland · Recruiting

  • US-Chapel Hill-UNCNORTHCAROLINA

    Chapel Hill, North Carolina · Recruiting

  • US-Cincinnati OH-CINCY

    Cincinnati, Ohio · Recruiting

  • US-Colombus OH-OSU

    Columbus, Ohio · Recruiting

  • US-Portland OR-OHSU

    Portland, Oregon · Not yet recruiting

  • US-Pittsburgh PA-PITT

    Pittsburgh, Pennsylvania · Recruiting

  • US-Dallas TX-SOUTHWESTERN

    Dallas, Texas · Not yet recruiting

  • US-Wheeling WV-WVU

    Wheeling, West Virginia · Recruiting

  • AU-Adelaide-RAH

    Adelaide, Australia · Recruiting

  • AU-Birtinya-SUNSHINECOASTUH General Information

    Birtinya, Australia · Recruiting

  • AU-Brisbane-RBWH

    Brisbane, Australia · Recruiting

  • AU-Douglas-TOWNSVILLE

    Douglas, Australia · Recruiting

  • AU-Melbourne-ALFRED

    Melbourne, Australia · Recruiting

  • AU-Melbourne-MONASH

    Melbourne, Australia · Recruiting

  • AU-Perth-FSH

    Perth, Australia · Withdrawn

  • AU-Perth-SCGH

    Perth, Australia · Recruiting

  • AU-Sydney-RNSH

    Sydney, Australia · Recruiting

  • AU-Sydney-SVSH

    Sydney, Australia · Not yet recruiting

  • AT-Feldkirch-IKHF

    Feldkirch, Austria · Recruiting

  • AT-Linz-KEPLER

    Linz, Austria · Not yet recruiting

  • AT-Salzburg-SALK

    Salzburg, Austria · Not yet recruiting

  • AT-Vienna-HANUSCH

    Vienna, Austria · Recruiting

  • BE-Antwerpen-ZAS

    Antwerp, Belgium · Recruiting

  • BE-Brugge-AZBRUGGE

    Bruges, Belgium · Recruiting

  • BE-Brussel-BORDET

    Brussels, Belgium · Recruiting

  • BE-Brussel-UZBRUSSEL

    Brussels, Belgium · Recruiting

  • BE-Bruxelles-STLUC

    Brussels, Belgium · Recruiting

  • BE-Gent-UZGENT

    Ghent, Belgium · Recruiting

  • BE-Hasselt-VIRGAJESSE

    Hasselt, Belgium · Not yet recruiting

  • BE-Leuven-UZLEUVEN

    Leuven, Belgium · Recruiting

  • BE-Liege-CHULIEGE

    Liège, Belgium · Recruiting

  • BE-Yvoir-MONTGODINNE

    Yvoir, Belgium · Recruiting

  • DK-Aalborg-AALBORGUH

    Aalborg, Denmark · Not yet recruiting

  • DK-Aarhus N-AUH

    Aarhus N, Denmark · Recruiting

  • DK-Copenhagen-RIGSHOSPITALET

    Copenhagen, Denmark · Not yet recruiting

  • DK-Odense-OUH

    Odense, Denmark · Not yet recruiting

Showing 40 of 199 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.